ASIX

AdvanSix is a classic commodity-chemical cyclical (Nylon 6, caprolactam, ammonium sulfate, phenol/acetone) trading at a genuinely low valuation: 11.3x EPS, 0.4x sales, and roughly 0.67x book (equity $815M vs. $545M market cap). Revenue has flatlined at $1.52B for three straight years after peaking at $1.95B in 2022, and earnings sit near trough — net income of $49.3M and $1.80 EPS are a fraction of the $172M/2022 peak. The company itself frames the story in its risk factors: 'the cyclical nature of the industries in which we operate,' with periods of tight supply and fat margins followed by oversupply and falling prices, and 'no assurance that pricing or profitability in the future will be comparable to any historical period.' At this price you are buying a low-quality but cheap asset near the bottom of its cycle.

Quality is the problem. ROE is just 6.0% and net margin 3.2%, and the 11.6% net-income 'growth' is flattered by a one-time item — MD&A discloses ~$26M of insurance settlement proceeds from the Philadelphia Energy Solutions shutdown booked in Q1 2025. Strip that and underlying earnings barely moved. Cash generation is the real constraint: operating cash flow of $123M was almost entirely consumed by $116M of capex, leaving only ~$7M of free cash flow — not enough to cover the $17.2M dividend, which is effectively being funded off the balance sheet and the $500M revolver. Cash on hand is a thin $19.8M against $891M of liabilities.